ScholarWorks@Hanyang University: Choi, Hojin

Detailed Information

Choi, Hojin (최호진)

COLLEGE OF MEDICINE (DEPARTMENT OF NEUROLOGY)

Research Area

Tel 031-560-2260
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Dementia:7||Phosphatidylinositol 3kinase:4||Neural stem cells:4||Virtual Reality:4||s disease:4||Alzheimer&apos:3||dementia:3||Neurologists:3||Ischemic stroke:3||Planning:3||Policy:3||Tower of London:2||Alzheimer’s disease:2||Neuroprotection:2||Coenzyme Q10:2||Cognitive Impairment:2||Care:2||virtual reality:2||AcetylLcarnitine:2||Embodied cognition:2||Embodied Cognition:2||cognition:2||mild cognitive impairment:2||Executive Function:2||Executive Functions:2||Executive function:2||Stroke:2||phosphatidylinositol3 kinase:2||prognosis:2||antiinflammatory:2||antinociceptive:2||Calcineurin inhibitor:1||Caregiver:1||Cerebellar Ataxia:1||Cerebral Infarction:1||Cervical thymoma:1||Cilostazol:1||Clopidogrel bisulfate:1||Clopidogrel resinate:1||Cognitive training:1||Colorcategory Interference:1||Cyclosporine:1||Cytotoxic lesions of the corpus callosum:1||DHP1401:1||Daily life:1||Daily task:1||Day care center:1||Dementia support center:1||EEG:1||Early onset dementia:1||Ecological validity:1||Efficacy:1||Embodied Behavior:1||Emergency medical services:1||Emergency room:1||Executive functions (EF):1||Extracellular signalrelated kinase:1||GV1001 peptide:1||Glutaredoxin:1||Gout:1||HIRA:1||Health Care System:1||Highresolution MRI:1||Hypoxia:1||Incidence:1||Inhibition:1||Instrumental Activities of Daily Living:1||Issue 134:1||Kinematics:1||Korea:1||LGR5:1||MIF:1||MMP9:1||Matrix metalloproteinase9:1||Medication Adherence:1||Meningioma:1||Metabolic syndrome:1||Microglia:1||Microscopic polyangiitis:1||Mild Cognitive Impairment:1||MoCAK:1||Models:1||Morning surge:1||Motion Capture:1||Motor neuron disease:1||Moving Distance:1||Multiple Errands Test (MET):1||Myasthenia gravis:1||National Health Insurance Service:1||National health insurance service:1||National responsibility policy:1||Neural Stem Cell:1||Neuroblastoma:1||Neurons:1||Neuropsychological Assessment:1||Nocturnal dipping:1||Nystagmus:1||Oxidative stress:1||Oxygen glucose deprivation:1||PI3K:1||Parkinson&apos:1||Patient Compliance:1||Peroneal neuropathy:1||Phenomenology of MerleauPonty’s Perception:1||Phospholipid:1||Phryma leptostachya var. asiatica Hara:1||Pituitary adenoma:1||Pontine infarction:1||Prevalence:1||Prognosis:1||Progressive motor deficit:1||Progressive multifocal leukoencephalopathy:1||Proliferation:1||Reactive oxygen species:1||Residency:1||Scale:1||Serum deprivation:1||Shifting, Behavioral data:1||Silent brain infarcts:1||Skin whitening:1||Statin:1||Steroid therapy:1||Stroop test:1||Systemic sclerosis:1||Thymectomy:1||Time to Completion:1||TolosaHunt syndrome:1||Trajectory:1||Treatment Adherence and Compliance:1||Uric acid:1||VR:1||Vascular Cognitive Impairment:1||Viability:1||Virtual Environment (VE):1||Virtual Mall:1||Virtual reality:1||Wakeup stroke:1||Working memory:1||Workload:1||academic trends:1||activities of daily living:1||amyloid:1||amyloid beta:1||animal:1||antiNmethylDaspartate receptor encephalitis:1||antiangiogenic:1||antiphospholipid syndrome.:1||biomarkers:1||brain disorder:1||brain imaging:1||calcium channel blocker:1||candesartan:1||caregiver:1||case report:1||cerebral infarct:1||clinical trial:1||cognitive ability:1||cognitive function:1||cognitive impairment:1||community management rate:1||communitybased cognitive intervention program:1||complexity:1||cyclooxygenase2:1||diagnostic screening program:1||digital health:1||digital markers:1||executive function:1||eye movement:1||fermentation:1||frontotemporal dementia:1||functional connectivity:1||glycogen synthase kinase3 (GSK3):1||graph analysis:1||hand movement:1||hippocampus:1||hnRNP:1||hypoxia:1||immersive:1||inducible nitric oxide synthase:1||l3:1||machine learning:1||methotrexate:1||mild to moderate AD:1||motor neuron disease:1||neural stem cells:1||neural stem cells.:1||neurology:1||neuropsychological test:1||neurotoxicity:1||nitric oxide:1||ovarian teratoma:1||policy:1||quality of life:1||randomized placebocontrolled clinical trial:1||reactive oxygen species:1||red ginseng:1||sTREM2:1||screening:1||spectral power:1||stem cell therapy.:1||stroke:1||sublethal dose:1||treatment:1||white matter hyperintensities:1||.:1||zinc:1||19 vaccination:1||4dihydroxyphenylalanine (LDOPA):1||Acquired immune deficiency syndrome:1||Activities of daily living:1||Acute motor axonal neuropathy:1||Alzheimer Disease:1||Alzheimer disease:1||Ambulatory blood pressure monitoring:1||Amlodipine besylate:1||Amyloid beta:1||Amyloidbeta:1||Amyotrophic lateral sclerosis:1||AntiGD1b antibody:1||Antiangiogenic:1||Antiinflammatory:1||Anticipatory Dementia:1||Antioxidant:1||Anxiety:1||Apoptosis:1||Aspirin:1||Assessment:1||Atrophy:1||Basilar plaque:1||Behavior:1||Benidipine hydrochloride:1||Bifidobacterium:1||Body:1||COVID:1||COVID19:1||Calcification:1||

STATISTICS: Total View :4,923,608; Today View :2,952

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE